Literature DB >> 25126271

Alzheimer's disease: a healthcare burden of epidemic proportion.

T S Dharmarajan1, Srinivas G Gunturu2.   

Abstract

Alzheimer's disease is the most common cause of dementia and increases in prevalence exponentially with age, with trends in the United States likely to worsen in ensuing decades. The pathology in Alzheimer's disease is characterized by an increase in extracellular amyloid plaques and intraneural neurofibrillary tangles, with neuronal destruction in several areas of the brain, and biochemically by a deficiency in acetylcholine; clinical manifestations include progressive loss of memory, change in personality, and behavioral disturbances. Pharmacotherapy includes the T.S. Dharmarajan Srinivas G. Gunturu use of cholinesterase inhibitors and memantine; addressing the many behavioral manifestations of the disease, especially in advanced stages, imposes tremendous burden to caregivers and healthcare resources.

Entities:  

Year:  2009        PMID: 25126271      PMCID: PMC4106591     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN: 1942-2962


  35 in total

Review 1.  Alzheimer's disease.

Authors:  Jeffrey L Cummings
Journal:  N Engl J Med       Date:  2004-07-01       Impact factor: 91.245

2.  Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians.

Authors:  Amir Qaseem; Vincenza Snow; J Thomas Cross; Mary Ann Forciea; Robert Hopkins; Paul Shekelle; Alan Adelman; David Mehr; Kenneth Schellhase; Doug Campos-Outcalt; Pasqualina Santaguida; Douglas K Owens
Journal:  Ann Intern Med       Date:  2008-03-04       Impact factor: 25.391

Review 3.  Epidemiology of dementia and Alzheimer's disease.

Authors:  H C Hendrie
Journal:  Am J Geriatr Psychiatry       Date:  1998       Impact factor: 4.105

Review 4.  Physical activity and Alzheimer's disease: from prevention to therapeutic perspectives.

Authors:  Yves Rolland; Gabor Abellan van Kan; Bruno Vellas
Journal:  J Am Med Dir Assoc       Date:  2008-06-02       Impact factor: 4.669

5.  Anticholinergic activity of 107 medications commonly used by older adults.

Authors:  Marci L Chew; Benoit H Mulsant; Bruce G Pollock; Mark E Lehman; Andrew Greenspan; Ramy A Mahmoud; Margaret A Kirshner; Denise A Sorisio; Robert R Bies; Georges Gharabawi
Journal:  J Am Geriatr Soc       Date:  2008-05-26       Impact factor: 5.562

Review 6.  Cost-effective recognition and diagnosis of dementia.

Authors:  David S Geldmacher
Journal:  Semin Neurol       Date:  2002-03       Impact factor: 3.420

7.  Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial.

Authors:  Marielle H Emmelot-Vonk; Harald J J Verhaar; Hamid R Nakhai Pour; André Aleman; Tycho M T W Lock; J L H Ruud Bosch; Diederick E Grobbee; Yvonne T van der Schouw
Journal:  JAMA       Date:  2008-01-02       Impact factor: 56.272

8.  The economic burden of Alzheimer's disease care.

Authors:  D P Rice; P J Fox; W Max; P A Webber; D A Lindeman; W W Hauck; E Segura
Journal:  Health Aff (Millwood)       Date:  1993       Impact factor: 6.301

Review 9.  PET studies in dementia.

Authors:  Karl Herholz
Journal:  Ann Nucl Med       Date:  2003-04       Impact factor: 2.668

10.  Medicare Part D and nursing home residents.

Authors:  David G Stevenson; Haiden A Huskamp; Nancy L Keating; Joseph P Newhouse
Journal:  J Am Geriatr Soc       Date:  2007-07       Impact factor: 5.562

View more
  5 in total

Review 1.  Addenbrooke's cognitive examination III in the diagnosis of dementia: a critical review.

Authors:  Diana Bruno; Sofia Schurmann Vignaga
Journal:  Neuropsychiatr Dis Treat       Date:  2019-02-15       Impact factor: 2.570

Review 2.  Alzheimer's disease: An evolving understanding of noradrenergic involvement and the promising future of electroceutical therapies.

Authors:  Cody Slater; Qi Wang
Journal:  Clin Transl Med       Date:  2021-04

3.  No increased risk of Alzheimer's disease among people with immune-mediated inflammatory diseases: findings from a longitudinal cohort study of U.S. older adults.

Authors:  Michael J Booth; Lindsay C Kobayashi; Mary R Janevic; Daniel Clauw; John D Piette
Journal:  BMC Rheumatol       Date:  2021-11-12

4.  Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis.

Authors:  Jana Janssens; Yannick Vermeiren; Erik Fransen; Tony Aerts; Debby Van Dam; Sebastiaan Engelborghs; Peter P De Deyn
Journal:  Alzheimers Dement (Amst)       Date:  2018-02-06

5.  Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory.

Authors:  Tigran Makunts; Sama Alpatty; Kelly C Lee; Rabia S Atayee; Ruben Abagyan
Journal:  Sci Rep       Date:  2019-11-21       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.